Cook Medical To Open New U.S. Medical Device Manufacturing Plant in Canton, IL

U.S. Sen. Dick Durbin, Cook Medical President Kem Hawkins to dedicate $19M high-tech manufacturing plant that bucks recent U.S. trend of increased overseas medical production

Cook Medical To Open New U.S. Medical Device Manufacturing Plant in Canton, IL

<0> Cook MedicalDavid McCarty, 812-322-1805 (mobile)Director, Global Public Relations </0>

At the opening of its newest U.S.-based manufacturing plant, Cook Medical President Kem Hawkins will discuss the impact reinvestment in small-town American cities such as Cook’s two plants in Canton, which have a combined investment cost of approximately $40 million, could have in reinvigorating America’s economy. Over its 49-year history, Cook has reinvested more than $1.5 billion in medical device manufacturing facilities that now employ about 10,000 in the U.S. and in select sites overseas, a growth strategy Cook executives hope to continue.

Other speakers will include U.S. Senator Dick Durbin, D-IL, U.S. Rep. Bobby Schilling, R-IL, and Canton Mayor Kevin Meade, whose remarks will focus on the remarkable turnaround his city has experienced thanks to Cook’s vision of building small-scale medical manufacturing plants in small communities where a high-skill workforce and other economic development assets are readily available.

A global pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving 41 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first,Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit . Follow Cook Medical on and

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.